Kalvista Pharmaceuticals Stock Buy Hold or Sell Recommendation
| KALV Stock | USD 8.30 0.05 0.61% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Kalvista Pharmaceuticals is 'Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Kalvista Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Kalvista Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Kalvista Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Kalvista and provide practical buy, sell, or hold advice based on investors' constraints. Kalvista Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Kalvista |
Execute Kalvista Pharmaceuticals Buy or Sell Advice
The Kalvista recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Kalvista Pharmaceuticals. Macroaxis does not own or have any residual interests in Kalvista Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Kalvista Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Kalvista Pharmaceuticals Trading Alerts and Improvement Suggestions
| Kalvista Pharmaceuticals generated a negative expected return over the last 90 days | |
| Kalvista Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (126.64 M) with loss before overhead, payroll, taxes, and interest of (93.47 M). | |
| Kalvista Pharmaceuticals currently holds about 142.08 M in cash with (89.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78. | |
| Kalvista Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
Kalvista Pharmaceuticals Returns Distribution Density
The distribution of Kalvista Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Kalvista Pharmaceuticals' future price movements. The chart of the probability distribution of Kalvista Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Kalvista Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Kalvista Pharmaceuticals returns is essential to provide solid investment advice for Kalvista Pharmaceuticals.
| Mean Return | -0.45 | Value At Risk | -5.26 | Potential Upside | 6.22 | Standard Deviation | 3.77 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Kalvista Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Kalvista Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Kalvista Pharmaceuticals, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Kalvista Pharmaceuticals back and forth among themselves.
| Shares | Mpm Oncology Impact Management Lp | 2024-09-30 | 896.9 K | Emerald Advisers, Llc | 2024-09-30 | 836 K | Geode Capital Management, Llc | 2024-09-30 | 831 K | Dafna Capital Management Llc | 2024-09-30 | 723.7 K | Emerald Mutual Fund Advisers Trust | 2024-09-30 | 651 K | Woodline Partners Lp | 2024-09-30 | 608.3 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 607 K | Silverarc Capital Management, Llc | 2024-09-30 | 574.6 K | Saturn V Capital Management Llc | 2024-09-30 | 556.5 K | Vr Adviser, Llc | 2024-09-30 | 6.2 M | Tang Capital Management Llc | 2024-09-30 | 4.3 M |
Kalvista Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (16.2M) | 34.8M | (19.9M) | 25.5M | (24.4M) | 52.3M | |
| Free Cash Flow | (30.3M) | (79.1M) | (76.5M) | (89.7M) | (80.7M) | (76.7M) | |
| Depreciation | 512K | 537K | 564K | 718K | 816K | 126.4K | |
| Other Non Cash Items | 114K | 4.9M | 84K | (485K) | (557.8K) | (529.9K) | |
| Capital Expenditures | 220K | 82K | 931K | 1.2M | 443K | 491.4K | |
| Net Income | (29.1M) | (46.2M) | (82.3M) | (92.9M) | (126.6M) | (26.1M) | |
| End Period Cash Flow | 15.8M | 50.6M | 30.7M | 56.2M | 31.8M | 9.3M | |
| Change To Netincome | 4.2M | 6.4M | 13.2M | 8.4M | 4.0M | 3.8M | |
| Investments | 17.0M | (147.6M) | 58.8M | 42.6M | (84.7M) | (750.8K) |
Kalvista Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Kalvista Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Kalvista Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Kalvista stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.48 | |
β | Beta against Dow Jones | 0.77 | |
σ | Overall volatility | 3.81 | |
Ir | Information ratio | -0.13 |
Kalvista Pharmaceuticals Volatility Alert
Kalvista Pharmaceuticals exhibits very low volatility with skewness of 0.62 and kurtosis of 0.16. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Kalvista Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Kalvista Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Kalvista Pharmaceuticals Fundamentals Vs Peers
Comparing Kalvista Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Kalvista Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Kalvista Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Kalvista Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Kalvista Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Kalvista Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Kalvista Pharmaceuticals to competition |
| Fundamentals | Kalvista Pharmaceuticals | Peer Average |
| Return On Equity | -0.91 | -0.31 |
| Return On Asset | -0.54 | -0.14 |
| Current Valuation | 280.61 M | 16.62 B |
| Shares Outstanding | 49.42 M | 571.82 M |
| Shares Owned By Insiders | 1.35 % | 10.09 % |
| Shares Owned By Institutions | 98.65 % | 39.21 % |
| Number Of Shares Shorted | 7.45 M | 4.71 M |
| Price To Earning | (2.82) X | 28.72 X |
| Price To Book | 3.06 X | 9.51 X |
| Price To Sales | 107.42 X | 11.42 X |
| Gross Profit | (93.47 M) | 27.38 B |
| EBITDA | (134.28 M) | 3.9 B |
| Net Income | (126.64 M) | 570.98 M |
| Cash And Equivalents | 142.08 M | 2.7 B |
| Cash Per Share | 5.78 X | 5.01 X |
| Total Debt | 7.32 M | 5.32 B |
| Debt To Equity | 0.05 % | 48.70 % |
| Current Ratio | 17.51 X | 2.16 X |
| Book Value Per Share | 4.86 X | 1.93 K |
| Cash Flow From Operations | (89.23 M) | 971.22 M |
| Short Ratio | 23.75 X | 4.00 X |
| Earnings Per Share | (3.68) X | 3.12 X |
| Target Price | 27.88 | |
| Number Of Employees | 150 | 18.84 K |
| Beta | 0.91 | -0.15 |
| Market Capitalization | 410.17 M | 19.03 B |
| Total Asset | 235.4 M | 29.47 B |
| Retained Earnings | (469.73 M) | 9.33 B |
| Working Capital | 202.88 M | 1.48 B |
| Current Asset | 54.95 M | 9.34 B |
| Current Liabilities | 4.27 M | 7.9 B |
| Net Asset | 235.4 M |
Note: Disposition of 7627 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 9.75 subject to Rule 16b-3 [view details]
Kalvista Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Kalvista . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Kalvista Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Kalvista Pharmaceuticals? Buying financial instruments such as Kalvista Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Kalvista Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Automobiles and Trucks Thematic Idea Now
Automobiles and Trucks
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Automobiles and Trucks theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Automobiles and Trucks Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.